Linagliptin Krka

Linagliptin, the active ingredient in Linagliptin Krka, is a DPP-4 inhibitor presented as an oral tablet for oral use. It is used to improve glycaemic control in adults with type 2 diabetes mellitus.

GNH USA supplies Linagliptin Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is indicated for the management of type 2 diabetes mellitus, acting on the incretin pathway to lower blood glucose.

- Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose when used with diet and exercise. - Type 2 diabetes mellitus (combination therapy): adds glucose‑lowering effect when combined with other oral antidiabetics or insulin. - Type 2 diabetes mellitus with renal impairment: provides effective glycaemic control without dose adjustment in patients with reduced kidney function.

Common Side Effects: - Nasopharyngitis: mild upper respiratory tract infection symptoms. - Headache: transient mild to moderate pain. - Dizziness: occasional light‑headedness. - Gastrointestinal upset: nausea, abdominal discomfort. - Back pain: musculoskeletal discomfort. - Arthralgia: joint pain.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe allergic reactions: rash, angioedema, anaphylaxis. - Hepatic injury: jaundice, elevated liver enzymes. - Bullous pemphigoid: blistering skin disorder. - Hypersensitivity syndrome: fever, rash, organ involvement. - Acute renal failure: abrupt decline in kidney function.

Linagliptin should be used with consideration of the following precautions: - Renal function assessment: evaluate renal status before initiation. - Hepatic impairment: monitor liver enzymes in patients with liver disease. - Cardiovascular disease: use cautiously in patients with unstable heart conditions. - Pregnancy and lactation: avoid unless benefits outweigh potential risks. - Concomitant insulin or sulfonylureas: monitor for hypoglycaemia. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Linagliptin may interact with several medicines. Review the following categories:

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase linagliptin exposure. - Co‑administration with another DPP‑4 inhibitor: provides no additional benefit and raises risk of adverse events.

Moderate Interactions (Monitor Closely): - Insulin or sulfonylureas: increased risk of hypoglycaemia; adjust dose as needed. - Rifampin: may reduce linagliptin plasma concentrations. - Diuretics: may affect glucose control; monitor blood glucose. - Digoxin: slight increase in digoxin levels; observe for toxicity.